Background Prostate cancer is a significant public health issue in the United States. It is the
most commonly diagnosed non-skin cancer and the second leading cause of cancer death …

Prostate cancer incidence and mortality rates vary worldwide. In the United States, prostate
cancer is the most common malignancy affecting men and is the second-leading cause of …

Abstract In the United States, prostate cancer is the most commonly diagnosed non–skin
cancer and the second leading cause of cancer death. The American Cancer Society …

The increased use of prostate-specific antigen (PSA) in screening for preclinical disease
after 1985 is thought to be a major determinant of the changing patterns in prostate cancer …

Objective. To examine prostate cancer trends by demographic and tumor characteristics
because a comprehensive examination of recent prostate cancer incidence rates is lacking …

Recent changes in the incidence of prostate cancer in the United States are stunning and
unprecedented in magnitude. From 1989 to 1991 alone, age-adjusted incidence increased …

We reviewed prostate cancer trends prior to and during the prostate-specific antigen (PSA)
era using data reported from population-based tumor registries in the United States. On the …

National-level data that characterize contemporary prostate cancer patients are limited. We
used 2004–2005 data from the Surveillance, Epidemiology, and End Results Program to …

PURPOSE: We describe trends in prostate cancer mortality from 1980 to 1997, before and
after the introduction of serum prostate specific antigen (PSA) testing to the community …

Methods Surveillance, Epidemiology, and End Results Program data from the years 1973 to
1997 are presented. All newly diagnosed cases of prostate cancer found within the defined …